Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Verzoni, Elena
Iacovelli, Roberto
Rizzo, Mimma
Felici, Alessandra
Cascinu, Stefano
Di Lorenzo, Giuseppe
Cerbone, Linda
Ortega, Cinzia
Masini, Cristina
Giganti, Maria Olga
Lorusso, Vito
Messina, Caterina
Atzori, Francesco
De Vincenzo, Fabio
Sacco, Cosimo
Boccardo, Francesco
Valduga, Francesco
Massari, Francesco
Tassi, Renato
Procopio, Giuseppe
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[2] Univ Roma La Sapienza, Dept Radiol Oncol & Human Pathol, Oncol Unit, I-00185 Rome, Italy
[3] Cardarelli, Oncol, Naples, Italy
[4] Regina Elena Inst Canc Res, Rome, Italy
[5] Osped Riuniti Umberto I GM Lancisi & G Salesi, Azienda Osped Univ, Polytech Univ Marche Reg, Dept Med Oncol, Ancona, Italy
[6] Univ Naples Federico II, Dept Oncol, Naples, Italy
[7] San Camillo & Forlanini Hosp, Rome, Italy
[8] Inst Canc Res & Treatment, Turin, Italy
[9] Univ Modena & R Emilia, AO Univ Policl Modena, Modena, Italy
[10] Osped Niguarda Ca Granda, Milan, Italy
[11] Vito Fazzi Hosp, Inst Oncol, Lecce, Italy
[12] Osped Riuniti Bergamo, I-24100 Bergamo, Italy
[13] Univ Hosp Cagliari, Cagliari, Italy
[14] Ist Clin Humanitas, Dept Oncol, Milan, Italy
[15] Univ Hosp Udine, Udine, Italy
[16] Univ Genoa, Natl Inst Canc Res, Genoa, Italy
[17] Osped Civ Santa Chiara, Trento, Italy
[18] Univ Florence, Florence, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.431
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
431
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Progression free survival (PFS) and overall survival (OS) in patients receiving 3 targeted therapies (TTs) for metastatic renal-cell carcinoma (mRCC)
    Elena, V.
    Iacovelli, R.
    Santoni, M.
    Di Lorenzo, G.
    Cerbone, L.
    Ortega, C.
    Masini, C.
    Giganti, M. O.
    Messina, C.
    De Vincenzo, F.
    Procopio, G.
    [J]. BJU INTERNATIONAL, 2012, 110 : 5 - 5
  • [2] PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS RECEIVING 3 TARGETED THERAPIES (TTS) FOR METASTATIC RENAL-CELL CARCINOMA (MRCC)
    Iacovelli, R.
    Santoni, M.
    Di Lorenzo, G.
    Cerbone, L.
    Aglietta, M.
    Masini, C.
    Giganti, M. O.
    Messina, C.
    Sternberg, C. N.
    Procopio, G.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 270 - 271
  • [3] Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Halabi, S.
    Rini, B. I.
    Stadler, W. M.
    Small, E. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Castro, Daniela
    Tripathi, Nishita
    Sayegh, Nicolas
    Gebrael, Georges
    Li, Xiaochen
    Meza, Luis
    Zengin, Zeynep
    Chehrazi-Raffle, Alex
    Govindarajan, Ameish
    Dizman, Nazli
    Ebrahimi, Hedyeh
    Chawla, Neal
    Mercier, Benjamin
    Hsu, Joann
    Shi, Jessica
    Philip, Errol
    Bergerot, Cristiane
    Barragan-Carrillo, Regina
    Pal, Sumanta
    [J]. ONCOLOGIST, 2023, 28 : S5 - +
  • [5] OVERALL SURVIVAL (OS) IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS' SEQUENTIALLY TREATED WITH TARGETED THERAPIES (TTS)
    Procopio, G.
    Verzoni, E.
    Testa, I.
    de Braud, F.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 24 - 24
  • [6] Progression-free survival (PFS) and overall survival (OS) across ethnicities for patients with metastatic renal cell carcinoma (mRCC) receiving targeted therapies (TT) as first-line (1L) treatment
    Salgia, Nicholas
    Dizman, Nazli
    Bergerot, Paulo Gustavo
    Bergerot, Cristiane Decat
    Hsu, Joann
    Pal, Sumanta K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [7] Progression-free survival (PFS) of first-line VEGF-targeted therapy as a prognostic parameter for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
    Seidel, C.
    Fenner, M.
    Reuter, C. W.
    Ganser, A.
    Gruenwald, V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Use of early tumor shrinkage as a response to VEGF inhibitors as a predictor of progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Gruenwald, Viktor
    Seidel, Christoph
    Fenner, Martin
    Woike, Michael
    Kalanovic, Daniel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Progression-free survival (PFS) as a surrogate for overall survival (OS)
    Stewart, David J.
    Bosse, Dominick
    Hilton, John
    Goss, Glenwood
    Fung-Kee-Fung, Michael
    Jonker, Derek
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [10] OVERALL SURVIVAL (OS) IN METASTATIC RENAL CELL CARCINOMA (MRCC) SEQUENTIALLY TREATED WITH DIFFERENT TARGETED THERAPIES (TTS): RESULTS FROM A LARGE COHORT OF PATIENTS
    Procopio, G.
    Verzoni, E.
    Testa, I.
    Iacovelli, R.
    Garanzini, E.
    De Braud, F. G. M.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 272 - 273
12345